{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:25:08Z","timestamp":1754486708453,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cjco.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:14:15Z","timestamp":1715822055000},"page":"1035-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiac Safety of Ozanimod Use, a Novel Sphingosine-1-Phosphate Receptor Ligand, in COVID-19 Patients Requiring Oxygen: Secondary Analysis of the COZI Randomized Clinical Trial"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-734X","authenticated-orcid":false,"given":"Guillaume","family":"Domain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Blais-Lecours","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Strub\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dognin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Ch\u00e2teauvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mie","family":"Savard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuyen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Marsolais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Lellouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2024.05.002_bib1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjco.2024.05.002_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cjco.2024.05.002_bib3","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1093\/ibd\/izy189","article-title":"Clinical pharmacology in adult and pediatric inflammatory bowel disease","volume":"24","author":"Hemperly","year":"2018","journal-title":"Inflamm Bowel Dis"},{"author":"Mohammed","key":"10.1016\/j.cjco.2024.05.002_bib4"},{"key":"10.1016\/j.cjco.2024.05.002_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12931-015-0180-z","article-title":"Treatment with a sphingosine analog after the inception of house dust mite-induced airway inflammation alleviates key features of experimental asthma","volume":"16","author":"Gendron","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.cjco.2024.05.002_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/mi.2017.37","article-title":"A\u00a0sphingosine-1-phosphate receptor 1 agonist inhibits tertiary lymphoid tissue reactivation and hypersensitivity in the lung","volume":"11","author":"Hupp\u00e9","year":"2018","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.cjco.2024.05.002_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cjco.2024.05.002_bib8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cjco.2024.05.002_bib9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.chest.2023.10.023","article-title":"Ozanimod therapy in patients with COVID-19 requiring oxygen support: a randomized, open-label, pilot trial","volume":"165","author":"Lellouche","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.cjco.2024.05.002_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1056-8719(03)00008-X","article-title":"How to correct the QT interval for the effects of heart rate in clinical studies","volume":"48","author":"Davey","year":"2002","journal-title":"J\u00a0Pharmacol Toxicol Methods"},{"key":"10.1016\/j.cjco.2024.05.002_bib11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjco.2024.05.002_bib12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjco.2024.05.002_bib13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjco.2024.05.002_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","article-title":"The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh","volume":"5","author":"Koyrakh","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cjco.2024.05.002_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cjco.2024.05.002_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpdd.383","article-title":"Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT\/QTc study","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cjco.2024.05.002_bib17","first-page":"173","article-title":"Circadian variations of sinus rate in subjects with sinus node dysfunction","volume":"9","author":"Alboni","year":"1982","journal-title":"Chronobiologia"},{"key":"10.1016\/j.cjco.2024.05.002_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40560-021-00552-w","article-title":"\u03b21-blocker in sepsis","volume":"9","author":"Hasegawa","year":"2021","journal-title":"J\u00a0Intensive Care"},{"key":"10.1016\/j.cjco.2024.05.002_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/ALN.0000000000003045","article-title":"Heart rate control during experimental sepsis in mice: comparison of ivabradine and \u03b2-blockers","volume":"132","author":"Bedet","year":"2020","journal-title":"Anesthesiology"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24002129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X24002129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T05:59:21Z","timestamp":1725947961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X24002129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2589790X24002129"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2024.05.002","relation":{},"ISSN":["2589-790X"],"issn-type":[{"type":"print","value":"2589-790X"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Safety of Ozanimod Use, a Novel Sphingosine-1-Phosphate Receptor Ligand, in COVID-19 Patients Requiring Oxygen: Secondary Analysis of the COZI Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}